The Audited Standalone and Consolidated financial results for the quarter and year ended 31st March 2026 were approved by the Board of Directors at its meeting held today.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 4.9 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indokem Ltd reported audited results for FY2026 with the statutory auditor CNK & Associates issuing an unmodified (clean) opinion on both standalone and consolidated results. Standalone total income fell marginally to Rs. 15,128 lakhs from Rs. 15,430 lakhs in FY25, a ~2% revenue decline. However, standalone PAT jumped sharply to Rs. 213 lakhs from Rs. 92 lakhs in the prior year, more than doubling. On a consolidated basis, total income declined to Rs. 17,245 lakhs from Rs. 17,881 lakhs, and consolidated PAT fell to Rs. 185 lakhs from Rs. 314 lakhs, showing the group underperformed the standalone company. The company took a one-time charge of Rs. 90.39 lakhs due to new labour codes. Non-current borrowings doubled to Rs. 2,472 lakhs from Rs. 1,192 lakhs year-on-year. Operating cash flow was negative at Rs. 368 lakhs (standalone) and Rs. 418 lakhs (consolidated). The board also reappointed key directors and approved policy changes.
Revenue pressure and weak consolidated profitability may concern investors, though the standalone PAT surge is a positive. The doubling of debt and negative operating cash flow are key watch items for financial health.